Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 5,058 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Alzheimer Disease, Healthy Volunteers
Interventions: LY2886721, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Diabetic Kidney Disease
Interventions: BMS-813160, Placebo matching with BMS-813160; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more

Conditions: Metastatic Non-Squamous Non-Small Cell Lung Cancer
Interventions: Nivolumab, Sitravatinib, Docetaxel; Biological · Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 133
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 109 more

Conditions: Bipolar I Disorder
Interventions: AL001, Lithium carbonate; Drug
Lead sponsor: Alzamend Neuro, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity
Interventions: Leu Sil 1.0mg, Leu Sil 4.0mg, Leu Met Sil 1.0mg, Leu Met Sil 4.0mg, Placebo; Drug
Lead sponsor: NuSirt Biopharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 15
States / cities: Mobile, Alabama • Montclair, California • Sacramento, California + 12 more

Conditions: Musculoskeletal Pain
Interventions: Vitamin D 2, Vitamin D2 Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Worcester, Massachusetts • St Louis, Missouri • Camden, New Jersey + 1 more

Conditions: Depressive Disorder, Major
Interventions: Placebo, JNJ-42847922; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 33
States / cities: Anaheim, California • Chino, California • Lemon Grove, California + 24 more

Conditions: Non-Small Cell Lung Cancer
Interventions: pemetrexed, nivolumab, paclitaxel, veliparib, carboplatin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 6
States / cities: Birmingham, Alabama • Whittier, California • Aurora, Colorado + 3 more

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: Canagliflozin, Placebo; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 54
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Avondale, Arizona + 51 more

Conditions: Acute Kidney Injury, Adverse Drug Event
Interventions: Melatonin, Placebo Capsule; Drug · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: New Brunswick, New Jersey • Somerville, New Jersey

Conditions: Thyroid Cancer, Thyroid Nodule, Thyroid Neoplasms, Thyroid Goitre, Thyroid Diseases, Parathyroid Diseases, Parathyroid Adenoma, Parathyroid Hyperplasia
Interventions: Acetaminophen 500Mg Cap, Tylenol #3 Oral Tablet, Tramadol; Drug
Lead sponsor: Minerva A Romero Arenas; Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Edinburg, Texas

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Very High Risk Myelodysplastic Syndrome
Interventions: Edetate Calcium Disodium, Multivitamin, Succimer; Drug · Dietary Supplement
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 1 Year and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Rheumatoid Arthritis
Interventions: fish oil, borage seed oil, combination fish oil and borage seed oil; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 13
States / cities: Birmingham, Alabama • Trumbull, Connecticut • Boca Raton, Florida + 9 more

Conditions: Schizophrenia
Interventions: PF-02545920, Placebo, Risperidone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 38
States / cities: Little Rock, Arkansas • Anaheim, California • Escondido, California + 23 more

Conditions: Schizophrenia
Interventions: Xanomeline and Trospium Chloride Capsules; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 34
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 27 more

Conditions: Relapsed or Refractory Peripheral T Cell Lymphoma
Interventions: golidocitinib; Drug
Lead sponsor: Dizal Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 4
States / cities: New Haven, Connecticut • Atlanta, Georgia • St Louis, Missouri + 1 more

Conditions: Lymphoma, Large B-Cell, Diffuse
Interventions: Durvalumab, Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone, Lenalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 7
States / cities: Gilbert, Arizona • Fort Wayne, Indiana • Rochester, Minnesota + 4 more

Conditions: Healthy
Interventions: Placebo, Methylphenidate, Nicotine; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT005 MDI, Formoterol Fumarate 12 μg (Foradil® Aerolizer®), Formoterol Fumarate 24 μg (Foradil® Aerolizer®), Placebo MDI; Drug · Other
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 3
States / cities: Clearwater, Florida • Tampa, Florida • Spartanburg, South Carolina

Conditions: Solid Malignancies
Interventions: AZD1480; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Aurora, Colorado • Detroit, Michigan • Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Type 2
Interventions: Pioglitazone 15 mg, Pioglitazone 45 mg, Pioglitazone 30 mg, Linagliptin 5mg / Pioglitazone 45 mg FDC, Linagliptin 5mg / Pioglitazone 30 mg FDC, Linagliptin 5mg, Linagliptin 5mg / Pioglitazone 15 mg FDC; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 936 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 74
States / cities: Birmingham, Alabama • Montgomery, Alabama • Muscle Shoals, Alabama + 60 more

Conditions: Hip Dysplasia, Cerebral Palsy
Interventions: Proximal Femoral Resection Arthroplasty, Subtrochanteric Valgus Osteotomy; Procedure
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 7 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 5
States / cities: Phoenix, Arizona • Miami, Florida • Boston, Massachusetts + 2 more

Conditions: Menopause
Interventions: estrogen patch, Amino acids, Placebo Patch, Placebo pills; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 48 Years to 60 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HCV Infection
Interventions: ABT-333, ketoconazole, placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Waukegan, Illinois

Search by objective public record fields.

A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease

Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder

The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity

Vitamin D to ENhance TraUma REcovery

A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

Melatonin for Prevention of Kidney Injury

Minimizing Narcotic Analgesics After Endocrine Surgery

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

Treatment of Rheumatoid Arthritis With Marine and Botanical Oils

An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia

An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Effects of Commonly Used Medications on Mood and Choice

PT005 MDI Dose Ranging Versus Foradil Aerolizer Study

Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

A Randomized Control Trial of Hip Dislocation Techniques for Pediatric Patients With Cerebral Palsy

Estrogen and Serotonin on Changing Brain Chemistry

A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333